Pharma channel feed

As­traZeneca's Alex­ion to take new R&D space in biotech tow­er in New Haven

4 years ago

Am­gen and As­traZeneca de­but first Tezspire cam­paign with di­verse cast of an­i­mat­ed char­ac­ters

4 years ago
Marketing

J&J reach­es $99M opi­oid set­tle­ment with West Vir­ginia, gets cleared to ex­it opi­oid li­a­bil­i­ty law­suit

4 years ago
Law

War in Ukraine may re­quire sig­nif­i­cant tri­al changes, EMA says in new guid­ance

4 years ago

Bris­tol My­ers inks $11M deal to set­tle an­ti­com­pet­i­tive claims in HIV suit

4 years ago
Law

With more than 30 on­col­o­gy part­ners, Gilead lays out its 2030 vi­sion of 20 new ap­provals

4 years ago
R&D

DOJ in­ves­ti­gat­ing Bausch Health over plaque pso­ri­a­sis drug mar­ket­ing — re­port

4 years ago
FDA+

US judge rules that 'Texas two-step' bank­rupt­cy can't help J&J stop a new pro­posed talc law­suit

4 years ago
Law

Mer­ck wins break­through ther­a­py des­ig­na­tion for po­ten­tial pneu­mo­coc­cal vac­cine suc­ces­sor

4 years ago
FDA+

ICER finds blue­bird's po­ten­tial $2.1M gene ther­a­py cost-ef­fec­tive as FDA ad­comm sched­uled for June

4 years ago
FDA+

Bi­par­ti­san group of law­mak­ers call on 7 man­u­fac­tur­ers to make opi­oid over­dose an­ti­dote OTC

4 years ago

FDA ad­dress­es bio­phar­ma's di­ver­si­ty prob­lem with new draft guid­ance

4 years ago
FDA+

Bay­er, GSK, No­var­tis and Roche jump­start bio­mark­er can­cer or­ga­ni­za­tion to dri­ve tests for all

4 years ago
Marketing
Diagnostics

The nev­er-end­ing Zostavax sto­ry – in court. Mer­ck gets a win, but thou­sands more law­suits pend­ing

4 years ago
Marketing

Take­da makes good on buy­back promise, snap­ping up near­ly $200M of its own shares

4 years ago

CMS of­fi­cial on Alzheimer's drug cov­er­age de­ci­sion: Don't read be­tween the lines for oth­er ac­cel­er­at­ed ap­provals

4 years ago

Ab­b­Vie pres­i­dent Michael Sev­eri­no heads to Flag­ship as biotech in­cu­ba­tor's third CEO-part­ner in six days

4 years ago
People
Startups

Qui­et CD­MO makes noise, throw­ing down $500M for man­u­fac­tur­ing cam­pus and mov­ing for­ward with Chi­na op­er­a­tions

4 years ago
Manufacturing

In­side the UK's push to ad­dress the an­timi­cro­bial cri­sis with a Net­flix-style sub­scrip­tion mod­el

4 years ago

How a phar­ma com­pa­ny bought 2 ac­cel­er­at­ed ap­provals — nev­er ran con­fir­ma­to­ry tri­als — and cashed in un­til FDA said stop

4 years ago
FDA+

Drug pro­mo po­lice slap Bausch Health with un­ti­tled let­ter over pso­ri­a­sis drug TV and dig­i­tal mar­ket­ing

4 years ago
FDA+
Marketing

Abzena com­mits chunk of new $65M in­vest­ment to build out in hot North Car­oli­na scene

4 years ago
Manufacturing

What hap­pened to all the 'good' drug names? In­side the mod­ern day dilem­ma of Rx nam­ing

4 years ago
Marketing

Mar­ket­ingRx roundup: Coun­try mu­sic awards and more phar­ma ads; Bris­tol My­ers ad­vances clin­i­cal tri­al di­ver­si­ty ef­fort

4 years ago
Marketing
First page Previous page 208209210211212213214 Next page Last page
A service from the Financial Times